Your session is about to expire
← Back to Search
Pembrolizumab + Chemotherapy for Brain Metastases from Lung Cancer
Study Summary
This trial will test whether the drug Pembrolizumab can help people with NSCLC and untreated brain metastasis live longer with fewer side effects.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2024 Phase 2 trial • 57 Patients • NCT03004183Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I do not have any unmanaged ongoing illnesses.You are expected to live for more than three months.My lung cancer does not have genetic mutations driving its growth.I have not experienced any new neurological symptoms.I have a serious wound, ulcer, or bone fracture that is not healing.I had a minor surgery, like a biopsy, within the last 3 days.Each abnormal area is three centimeters or smallerI have not had major surgery or a serious injury in the last 14 days.I have a serious heart condition.My cancer has spread to the lining of my brain and spinal cord.There is a shift in the middle of the brain.You are unable to take or finish tests that measure brain function.My cancer has specific genetic changes driving its growth.My organs and bone marrow are working well.I have had allergic reactions to certain antibody treatments.I have fewer than 10 brain lesions.My lung cancer has spread to my brain but I don't have symptoms.My cancer is near my optic nerve or in my brainstem.
- Group 1: Pembrolizumab with standard of care chemotherapy treatment
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there still openings in this experiment for participants?
"Yes, according to clinicaltrials.gov the trial is actively recruiting participants. It was initially posted on December 7th 2021 and updated most recently on January 18th 2022. The study requires 45 patients from 1 medical centre."
What indications are typically treated with Pembrolizumab?
"Pembrolizumab is predominantly utilised to combat malignant tumours, but it has also been proven effective in treating unresectable melanoma, microsatellite instability high and locally advanced non-squamous non-small cell lung cancer."
What potential adverse effects may be associated with Pembrolizumab?
"After careful consideration, the team at Power ascertained that Pembrolizumab's safety is rated a 2. This rating suggests that there is some evidence of its security but not yet any verification regarding efficacy."
Who qualifies to partake in this experiment?
"This trial is recruiting 45 individuals aged 18 to 85 suffering from malignancies. To be eligible, they must demonstrate acceptable organ and marrow function, have non-small cell lung cancer with untreated asymptomatic brain metastases that lack oncogenic driver mutations, display no new neurological symptoms, possess fewer than ten intracranial lesions of size three centimeters or less each, expect a life expectancy of over three months, and understand their consent document before signing it."
Does this research include participants aged under 30?
"According to the study's inclusion criteria, individuals aged 18 and above but under 85 are eligible for enrolment."
What is the amount of participants in this experiment?
"Affirmative. Per the information available on clinicaltrials.gov, this research study is still recruiting participants and was first posted on December 7th 2021 with its most recent update occurring January 18th 2022. This trial requires 45 patients from 1 centre to participate."
Share this study with friends
Copy Link
Messenger